Corporate Social Responsibility in Non- Controlled Joint Venture Assets: Why Corporate Boards Should Care
Bookmark

Corporate Social Responsibility in Non- Controlled Joint Venture Assets: Why Corporate Boards Should Care

$0.00

Water Street Partners

Category: Tags: , , , ,

Additional information

Language

Capability

Description

LAST YEAR, we wrote about why corporate Boards of Directors should care about their portfolios of non-controlled joint ventures. In short, these portfolios tend to be more material than realized, carry underappreciated and often inappropriately managed levels of risk, and contain latent performance upside – all of which are challenges to corporate Directors increasingly exposed collectively and personally to regulatory and shareholder scrutiny.

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.

You may also like

  • Capgemini

    The key promise of the Industry 4.0 concept is as striking as it is fascinating: we are about to witness a new industrial revolution, fueled by the advancement of digital technologies. The fusion of the physical and the virtual world into cyberphysical systems will have a disruptive impact on every business domain of manufacturing companies.

    Industry 4.0 – Sharpening the Picture beyond the Hype

    $0.00     Capgemini
  • AON

    Every Year Technologists, security professionals, and risk managers comment extensively “unprecedented” level of change we have or will experience as we move from year to year. In fact, change- and the proliferation of new threats- has become the only constant we can expect.

    2019 Cyber Security Risk Report

    $0.00     AON
  • McKinsey

    In 2007, medical leaders from across the pharmaceutical industry assembled to develop a common understanding of a ten-year vision for Medical Affairs. With five years now past, it is hardly surprising that significant change has occurred in the world in which the pharmaceutical industry operates, especially given the remarkable economic environment and the continued acceleration of technological change.

    Pharma Medical Affairs 2020 and beyond

    $0.00     McKinsey

Pin It on Pinterest

Loading..